$5.82
-0.04 (-0.68%)
Open$5.74
Previous Close$5.86
Day High$6.12
Day Low$5.60
52W High$9.37
52W Low$0.72
Volume—
Avg Volume1.82M
Market Cap48.92M
P/E Ratio—
EPS$-1.15
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+417.9% upside
Current
$5.82
$5.82
Target
$30.14
$30.14
$22.58
$30.14 avg
$41.69
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.48M | 2.49M | 2.71M |
| Net Income | -380,025 | -467,867 | -467,071 |
| Profit Margin | -15.3% | -18.8% | -17.2% |
| EBITDA | -552,767 | -558,041 | -685,415 |
| Free Cash Flow | -221,579 | -328,689 | -323,480 |
| Rev Growth | +22.9% | +23.1% | -7.6% |
| Debt/Equity | 0.29 | 0.26 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |